|
个人信息Personal Information
教授 博士生导师 硕士生导师
性别：男
毕业院校：山东大学
学历：研究生(博士)毕业
学位：医学博士学位
在职信息：在职
所在单位：药学院
入职时间：2013-02-28
联系方式：zhangyingjie@sdu.edu.cn
扫描关注
- [1] . Discovery of epigenetic modulators targeting HDACs and EZH2 simultaneously for the treatment of hematological malignancies. Bioorganic Chemistry, 153, 2024.
- [2] . Discovery of Novel Fedratinib-Based HDAC/JAK/BRD4 Triple Inhibitors with Remarkable Antitumor Activity against Triple Negative Breast Cancer. Journal of Medicianal Chemistry, 66, 2023.
- [3] . Discovery of the First Irreversible HDAC6 Isoform Selective Inhibitor with Potent Anti-Multiple Myeloma Activity. J. Med. Chem. , 66, 10080, 2023.
- [4] Anil Kumar Marapaka. Development of peptidomimetic hydroxamates as PfA-M1 and PfA-M17 dual inhibitors: Biological evaluation and structural characterization by cocrystallization. CHINESE CHEMICAL LETTERS, 2550, 2022.
- [5] 薛霞. Design, synthesis and biological evaluation of dual HDAC and VEGFR inhibitors as multitargeted anticancer agents. Investigational New Drugs , 40, 10-20, 2022.
- [6] 许启富. Inhibitors of the GTPase KRAS(G12C) in cancer: a patent review (2019-2021). Expert Opinion on Therapeutic Patents, 32, 475, 2022.
- [7] 李顺达. Development of selective HDAC6 inhibitors with in vitro and in vivo anti-multiple myeloma activity. Bioorganic Chemistry, 105278, 2021.
- [8] 刘倩. Design, Synthesis, and Biological Evaluation of APN and AKT Dual-Target Inhibitors. ACS Medicinal Chemistry Letters, 12, 1932, 2021.
- [9] 梁学武. Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies. 《Journal of Medicinal Chemistry》, 62, 3898, 2019.
- [10] 曹江营. Development of pyrazoline-based derivatives as aminopeptidase N inhibitors to overcome cancer invasion and metastasis. RSC ADVANCES, 11, 21426, 2021.
- [11] 丁钦阁. Synthesis and biological study of class I selective HDAC inhibitors with NO releasing activity. BIOORGANIC CHEMISTRY, 104, 2020.
- [12] 闫玉刚. In vivo pharmacokinetic study and oral glucose tolerance test of sulfoxide analogs of GPR40 agonist TAK-875. DRUG DEVELOPMENT RESEARCH, 81, 708, 2020.
- [13] 许启富. Discovery of a Novel Hybrid of Vorinostat and Riluzole as a Potent Antitumor Agent. Front. Cell Dev. Biol., 8, 2020.
- [14] 赵春龙. Histone deacetylase (HDAC) inhibitors in cancer: a patent review (2017-present). Expert Opinion on Therapeutic Patents, 30, 263, 2020.
- [15] 曹江营. Development of a Bestatin-SAHA Hybrid with Dual Inhibitory Activity against APN and HDAC. Molecules, 25, 2020.
- [16] 徐文方 , 张颖杰 and 董航. Design, Synthesis and Biological Evaluation of Novel Osimertinib-Based HDAC and EGFR Dual Inhibitors. Molecules, 24, 2407, 2019.
- [17] 张颖杰 and 梁学武. Novel-targeted therapy for hematological malignancies with JAK and HDAC dual inhibitors. Future Medicinal Chemistry, 11, 1849, 2019.
- [18] 刘新泳 , 徐文方 and 张颖杰. Discovery of N-Substituted Oseltamivir Derivatives as Potent and Selective Inhibitors of H5N1 Influenza Neuraminidase. J. Med. Chem, 2014.
- [19] 徐文方 and 张颖杰. Discovery of a pair of diastereomers as potent HDACs inhibitors: determination of absolute configuration, biological activity comparison and computational study. Rsc Adv., 2013.
- [20] 徐文方 and 张颖杰. Design and synthesis of a tetrahydroisoquinoline-based hydroxamate derivative (ZYJ-34v), an oral active histone deacetylase inhibitor with potent antitumor activity. Chem. Biol. Drug Des, 2013.